Longleaf Partners, managed by Southeastern Asset Management, released its “Small-Cap Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. Longleaf experienced several environments throughout its experience in small-cap investing. This year, the underlying developments in the Fund’s holdings were more promising than the actual stock price returns when compared to the target of inflation plus 10% and the unusual performance of the Russell 2000. In Q4 2025, the Fund returned ...

Core Viewpoint - Oscar Health Inc. (NYSE:OSCR) is identified as an under-the-radar AI stock with recent upgrades from analysts, indicating a positive outlook despite challenges related to expiring subsidies [1][2][3]. Analyst Upgrades - UBS upgraded Oscar Health from Sell to Neutral, raising the price target from $12 to $17, citing better-than-expected exchange enrollment performance [1]. - Barclays analyst Andrew Mok upgraded Oscar Health from Underweight to Equal Weight, increasing the price target from $13 to $18, anticipating benefits from margin expansion in managed care stocks by 2026 [2]. Market Positioning - Andrew Mok noted that Oscar Health is attractively priced due to the market over-discounting the negative impacts of expiring subsidies, suggesting potential for recovery [3]. - Oscar Health operates as a healthcare technology company in the US, providing health plans to individuals, families, employees, and small group markets [3].

Market Overview - The Dow Jones Industrial Average surged over 270 points to 50,407, marking a record high, while the S&P 500 and Nasdaq experienced slight declines of 0.09% and 0.42% respectively, indicating a rotation into blue-chip and defensive stocks [24][2] - Retail sales for December were flat at $735 billion, significantly below expectations, suggesting a cooling economy and impacting market sentiment [8][25] - The upcoming US jobs report and inflation data are critical for market direction, with expectations that a softer jobs number could reinforce the Dow's leadership [22][24] Sector Performance - The Dow's strength is attributed to its composition, favoring established companies in industrials, consumer staples, healthcare, and dividend payers, which tend to perform well in a slowing growth environment [2][3] - In contrast, the S&P 500 and Nasdaq are heavily weighted towards growth and megacap tech stocks, which are more sensitive to rate expectations and earnings visibility [3][2] Commodity Insights - Crude oil prices remained stable, with WTI crude at $64.31 and Brent crude at $67.98, as traders balanced weak demand signals against supply risks [4][24] - Gold prices hovered near historic levels at $5,078, supported by strong central bank buying and risk hedging, while silver prices fell to $81.94 due to profit booking [6][24] Cryptocurrency Market - The cryptocurrency market faced renewed selling pressure, with Bitcoin dropping 2.66% to $68,301 and the Nasdaq Crypto Index declining 3.27%, reflecting broad weakness across major tokens [10][11] - Analysts view the recent pullback in crypto as confidence-driven rather than a structural breakdown [11] Company-Specific Developments - Nvidia's stock remained steady at $190.35, supported by sustained AI demand and strong data-center spending, despite broader tech sentiment cooling [12][24] - Oscar Health's stock surged 12.40% to $14.23 following positive forward guidance and a path toward profitability [13][24] - Snap Inc. rose 2.60% to $5.33 as digital advertising demand showed early signs of stabilization [14][24] - Intel's stock fell 1.31% to $49.58, underperforming peers amid selective investor sentiment in the semiconductor sector [15][24] - Amazon.com slipped 0.64% to $207.38, reflecting a market rotation away from megacap growth stocks [16][24] Earnings Impact - Earnings reports contributed to the Dow's advance, with Coca-Cola reinforcing the appeal of predictable cash flows and CVS Health beating profit expectations while maintaining its full-year outlook [20][24] - Spotify's stock surged after upbeat forecasts, highlighting the importance of company-specific execution even in a softening broader market [21][24]

Oscar Health’s fourth-quarter loss widened as the health insurer continued to struggle with the high utilization of medical services by plan enrollees. https://t.co/qOOTxSQlC7 ...

Group 1 - Humana Inc. experienced a significant decline of 21.13 percent, closing at $207.93, following a flat funding announcement for Medicare Advantage in 2027 [1][4] - The Centers for Medicare & Medicaid Services (CMS) announced only a 0.09 percent increase in Medicare Advantage payments for the upcoming year, which is substantially lower than the anticipated 4 to 6 percent growth [2][3] - The decline in Humana's stock price is part of a broader trend affecting other insurance companies, including CVS Health, UnitedHealth Group, Centene Corp., and Oscar Health, due to concerns over profit margins impacted by the updated payment rates [4]

Group 1 - Alignment Healthcare Inc. (NASDAQ:ALHC) experienced a significant decline of 11.97% on Tuesday, closing at $20.96, as investors reacted negatively to lower-than-expected preliminary payment proposals for the Medicare Advantage program [1][3] - The Centers for Medicare and Medicaid Services (CMS) projected a net average payment increase of only 0.09%, which is substantially lower than the anticipated growth of 4 to 6 percent by analysts [2] - The CMS also proposed tighter risk-adjustment rules, including the exclusion of diagnoses made solely via audio calls and some chat reviews starting in 2027 [2] Group 2 - Alignment Healthcare's stock drop was in line with other major players in the industry, such as UnitedHealth Group, CVS Health, Centene Corp., and Oscar Health, raising concerns about their performance due to exposure to the government-sponsored Medicare program [3] - Investors are expected to monitor Alignment Healthcare's short-term outlook closely, particularly following updates to the Medicare program, with the company scheduled to release its financial and operating highlights in the last week of February 2026 [4]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Yesterday, US health insurance stocks took an almighty beating, as news broke that the Centers for Medicaid and Medicare Services ("CMS") had announced a proposed rate increase for Medicare Advantage ("MA") Capitat ...

Core Insights - UnitedHealth Group Incorporated (NYSE:UNH) is recognized as a Dividend Contender, being listed among the top 20 stocks in this category [1] Group 1: Strategic Moves and Industry Implications - Baird analyst Michael Ha described UnitedHealth's decision to rebate profits from its Affordable Care Act (ACA) business as a "potentially masterful move," indicating that this action is not expected to materially impact UNH's earnings for 2026 [2] - The strategic implications of this rebate could pressure competitors who rely more heavily on ACA exchange profitability, particularly companies like Centene (CNC), Molina Healthcare (MOH), and Oscar Health (OSCR) [3] - UnitedHealth plans to provide rebates to its Obamacare plan members in 2026, with CEO Stephen Hemsley confirming collaboration with the Trump administration on rebate structuring [4] Group 2: Market Position and Enrollment Expectations - For the 2026 plan year, UnitedHealthcare will offer ACA marketplace plans across 30 states, although management anticipates a significant decline in ACA enrollment, estimating a potential drop of about two-thirds [5] - UnitedHealth Group operates as a large, diversified global healthcare company, with two primary segments: UnitedHealthcare, which provides health insurance coverage, and Optum, which focuses on technology-driven health services and pharmacy benefits [6]

Company Overview - Oscar Health, Inc. (NYSE:OSCR) provides medical insurance plans for individuals, families, and small businesses [2] Recent Performance - Oscar Health reversed from being a contributor to a detractor in the third quarter of 2025, with claims losses being much worse than expected in the first half of the year [2] - The stock price exceeded $20 per share at the end of the second quarter, but July was a challenging month for Oscar and its industry [2] - As the stock recovered later in the quarter, the Longleaf Partners Small-Cap Fund sold the rest of its position, indicating a successful overall investment despite the volatility [2] Market Sentiment - Jim Cramer expressed a positive sentiment towards Oscar Health, indicating that the leadership of Bertolini is a significant factor in his bullish outlook [1] - There is a belief that certain AI stocks may offer greater upside potential compared to Oscar Health, suggesting a competitive landscape for investment opportunities [3]

Core Insights - The performance of the Southeastern Small-Cap Fund has been mixed, with the underlying developments of holdings being better than stock price returns, particularly in a challenging market environment [2][3] - The fund's portfolio has a lower percentage of big winners compared to the Russell 2000, with only 15% of its holdings up an average of 30% compared to over 35% of the index's holdings up 70%+ [3] - The fund has maintained a strong position in the mid-range performance category, outperforming the Russell 2000 in that segment [4] - The fund's exposure to decliners was limited, with only 10% of the portfolio in this category, resulting in lower average losses compared to the index [5] Performance Analysis - The fund's average performance in the -20% to +20% return bucket was better than the Russell 2000's 0% return, with key holdings like White Mountains, CNX, and Rayonier contributing positively [4] - The fund's cash position and stable investments like Kodak initially provided safety but later became performance headwinds [6] - The fund's leverage rules have been effective in avoiding pitfalls, and adjustments to the overweight rule have been made to enhance performance [7][8] Notable Contributors - Beclé, a tequila and whiskey manufacturer, was a significant contributor due to its undervaluation and strong market position [9] - GCI Liberty, a communications company in Alaska, benefited from its unique market position and insider support from John Malone [10] - Graham Holdings showed strong performance due to growth in its education and healthcare segments [11] - Mattel has positioned itself well with strong brand power and a robust balance sheet, leading to significant stock repurchases [12] - Oscar Health experienced above-market growth but was exited due to emerging industry risks [14] Notable Detractors - Boston Beer faced challenges due to declining volumes in its major brands, although management is actively addressing these issues [15] - Clearwater Paper struggled with a weak market for solid bleached sulfate paperboard, but management is focusing on share repurchases [16] - Park Hotels & Resorts was impacted by macroeconomic concerns affecting leisure travel, leading to a decision to exit the position [18] Portfolio Activity - The fund made seven new purchases during the year, including GCI Liberty and Beclé, while exiting eight positions, including Kodak and Oscar Health [20][19] Outlook - The fund anticipates continued engagement through research perspectives and podcasts, focusing on quality investments amid market volatility [21] - The fund's strategy emphasizes owning resilient, free cash flow-generating assets to navigate market fluctuations effectively [22]